Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

6.650 +0.270 (+4.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics: Another Sucess
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company. 
Via Talk Markets
Why Coya Therapeutics Shares Are Shooting Higher Today
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
From Coya Therapeutics, Inc.
Via Business Wire
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
Coya Therapeutics: An Attractive Valuation And First Set Of Data
Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions. 
Via Talk Markets
Alzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
Via ACCESSWIRE
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study 
Via News Direct
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
By David Willey, Benzinga 
Via TheNewswire.com
There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS). 
Via Benzinga
Coya Therapeutics: This BioPharma Company Has Some Big News To Share
Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc (NASDAQ: COYA), was a guest on Benzinga’s All Access. 
Via Benzinga
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
By David Willey, Benzinga 
Via TheNewswire.com
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development 
Via News Direct
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
By David Willey, Benzinga 
Via TheNewswire.com
Topics Death
Exposures Death
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study 
Via News Direct
Topics Death
Exposures Death
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.